← Back
$ARTV All transactions

Artiva Biotherapeutics, Inc.

A

$ Value

$0

Shares

13,750

Price

$0

Filed

Jun 26

Insider

Name

Stoppel Laura

Title

CIK

0001865119

Roles

Director

Transaction Details

Transaction Date

2025-06-24

Code

A

Table

Derivative

Ownership

Direct

Equity Swap

No

Shares After

13,750

Footnotes

The shares subject to the option will vest in full on the earlier of June 24, 2026, or the date of the Issuer's 2026 annual stockholder meeting. | Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the R.A. Capital Healthcare Fund, L.P. (the "Fund"), the R.A. Capital Nexus Fund, L.P. (the "Nexus Fund"), the RA Capital Nexus Fund III, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

Filing Info

Accession No.

0001415889-25-018280

Form Type

4

Issuer CIK

0001817241

Stoppel Laura's History

Date Ticker Type Value
2025-06-24 ARTV A $0
2025-06-04 ABOS A $0
2025-06-04 ABOS A $0

Other Insiders at ARTV (90d)

Insider Bought Sold Last
Bush Jennifer
COO, CLO, Secy, Compliance Off
2026-02-15
Huston Thad Allen
Chief Financial Officer
2026-03-10
Horan Christopher
Chief Tech Operations Officer
2026-02-15
Sorg Elaine K. 2026-02-18
Aslan Fred
President and CEO
2026-02-15
Raymon Heather
SVP, Research and Development
2026-02-15
Banerjee Subhashis
Chief Medical Officer
2026-02-15